Amendola Laura M, Robinson Jill O, Hart Ragan, Biswas Sawona, Lee Kaitlyn, Bernhardt Barbara A, East Kelly, Gilmore Marian J, Kauffman Tia L, Lewis Katie L, Roche Myra, Scollon Sarah, Wynn Julia, Blout Carrie
Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, WA, USA.
Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, TX, 77030, USA.
J Genet Couns. 2018 Sep;27(5):1220-1227. doi: 10.1007/s10897-018-0243-7. Epub 2018 Mar 1.
Clinical and research settings are increasingly incorporating genomic sequencing (GS) technologies. Previous research has explored reasons for declining genetic testing and participation in genetic studies; however, there is a dearth of literature regarding why potential participants decline participation in GS research, and if any of these reasons are unique to GS. This knowledge is essential to promote informed decision-making and identify potential barriers to research participation and clinical implementation. We aggregated data from seven sites across the National Institutes of Health's Clinical Sequencing Exploratory Research (CSER) consortium on each project's procedures for recruitment, and rates of and reasons for decline. Data were analyzed using descriptive statistics. The decline rate for enrollment at the seven CSER sites ranged from 12 to 64% (median 28%) and varied based on age and disease status. Projects differed in their protocols for approaching potential participants and obtaining informed consent. Reasons for declining GS research were reported for 1088 potential participants. Commonly cited reasons were similar to those reported for clinical single gene testing and non-GS genetic research. The most frequently cited reason for decline was study logistics (35%); thus, addressing logistical barriers to enrollment may positively impact GS study recruitment. Privacy and discrimination concerns were cited by 13% of decliners, highlighting the need for researchers and providers to focus educational efforts in this area. The potential psychological burden of pursuing and receiving results from GS and not wanting to receive secondary findings, a concern specific to GS, have been cited as concerns in the literature. A minority of potential participants cited psychological impact (8%) or not wanting to receive secondary findings (2%) as reasons for decline, suggesting that these concerns were not major barriers to participation in these GS studies. Further research is necessary to explore the impact, if any, of different participant groups or study protocols on rates of decline for GS studies. Future studies exploring GS implementation should consider using standardized collection methods to examine reasons for decline in larger populations and more diverse healthcare settings.
临床和研究环境越来越多地采用基因组测序(GS)技术。先前的研究探讨了基因检测减少以及参与基因研究的原因;然而,关于潜在参与者拒绝参与GS研究的原因,以及这些原因中是否有任何是GS所特有的,相关文献却很匮乏。这些知识对于促进明智的决策以及识别研究参与和临床实施的潜在障碍至关重要。我们汇总了来自美国国立卫生研究院临床测序探索性研究(CSER)联盟七个站点的数据,内容涉及每个项目的招募程序、拒绝率及拒绝原因。使用描述性统计方法对数据进行了分析。七个CSER站点的入组拒绝率在12%至64%之间(中位数为28%),并因年龄和疾病状态而异。各项目在接触潜在参与者和获得知情同意的方案上存在差异。1088名潜在参与者报告了拒绝GS研究的原因。常见原因与临床单基因检测和非GS基因研究报告的原因相似。最常被提及的拒绝原因是研究后勤(35%);因此,解决入组的后勤障碍可能会对GS研究的招募产生积极影响。13%的拒绝者提到了隐私和歧视问题,这凸显了研究人员和提供者在这一领域进行教育努力的必要性。文献中提到,追求并接收GS结果以及不想接收次要发现所带来的潜在心理负担是GS特有的问题。少数潜在参与者将心理影响(8%)或不想接收次要发现(2%)作为拒绝的原因,这表明这些问题并非参与这些GS研究的主要障碍。有必要进一步研究不同参与者群体或研究方案对GS研究拒绝率的影响(如果有的话)。未来探索GS实施的研究应考虑使用标准化收集方法,以在更大规模人群和更多样化的医疗环境中研究拒绝原因。